[1]苏比奴尔·阿不都克力木,秦旭阳,陆蕾,等.复肾泄浊方通过调节慢性肾脏病大鼠脂肪酸代谢改善肾纤维化机制研究[J].陕西中医,2026,(4):461-466,471.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.005]
　ABUDKELIMU Subinur,QIN Xuyang,LU Lei,et al.Mechanism of Fushen Xiezhuo recipe in ameliorating renal fibrosis in CKD rats by regulating fatty acid metabolism[J].,2026,(4):461-466,471.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.005]
点击复制

复肾泄浊方通过调节慢性肾脏病大鼠脂肪酸代谢改善肾纤维化机制研究

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年4期
页码:
461-466,471
栏目:
基础研究
出版日期:
2026-04-05

文章信息/Info

Title:
Mechanism of Fushen Xiezhuo recipe in ameliorating renal fibrosis in CKD rats by regulating fatty acid metabolism
作者:
苏比奴尔·阿不都克力木1; 秦旭阳1; 陆蕾1; 周蓓2; 李静茹1; 舒占钧3
（1.新疆医科大学第四临床医学院，新疆 乌鲁木齐 830000；2.新疆医科大学实验室与设备管理处动物实验中心，新疆 乌鲁木齐 830011；3.新疆医科大学附属中医医院，新疆 乌鲁木齐 830000）
Author(s):
ABUDKELIMU Subinur1; QIN Xuyang1; LU Lei1; ZHOU Bei2; LI Jingru1; SHU Zhanjun3
(1.The Fourth Clinical Medical College of Xinjiang Medical University,Urumqi 830000,China；2.Animal Experiment Center,Laboratory and Equipment Management Office,Xinjiang Medical University,Urumqi 830000,China；3.The Fourth Affiliated Hospital of Traditional Chinese Medicine of Xinjiang Medical University,Xinjiang Medical University,Urumqi 830000,China)
关键词:
肾纤维化; 慢性肾脏病; 脂肪酸代谢; 复肾泄浊方; 细胞凋亡; 线粒体代谢
Keywords:
Renal fibrosis; Chronic kidney disease; Fatty acid metabolism; Fushen Xiezhuo formula; Apoptosis; Mitochondrial metabolism
分类号:
R 285
DOI:
DOI:10.3969/j.issn.1000-7369.2026.04.005
文献标志码:
A
摘要:
目的：探讨复肾泄浊方（FSXZF）调节慢性肾脏病（CKD）大鼠脂肪酸代谢改善肾纤维化的机制。方法：将SPF级雄性SD大鼠32只随机分成空白组、模型组和FSXZF低、高剂量组，每组8只。除空白组外，余大鼠予腺嘌呤连续灌胃3周诱导建立CKD大鼠模型，FSXZF低、高剂量组大鼠分别予16.3、32.5 g/（kg·d）FSXZF灌胃4周。观察各组大鼠体重、肾脏指数；测定大鼠肾功能；HE及Masson染色观察肾组织病理改变；油红O染色观察脂质沉积；透射电镜观察线粒体超微结构。Western blot检测肾脏组织Bcl-2相关X蛋白（Bax）、细胞淋巴瘤2（Bcl-2）、半胱氨酸蛋白酶3（Caspase-3）、活化型Caspase-3（C-Caspase-3）的蛋白水平；Real-time PCR检测肾组织过氧化物酶体增殖物激活受体α（PPAR-α）、肉毒碱棕榈酰基转移酶1α（CPT1-α）mRNA水平。结果：与空白组相比，模型组大鼠体重下降，肾重及肾脏指数升高，肾功能指标明显减退（均P<0.05）；病理提示大鼠肾小球萎缩、基底膜增厚，肾小管扩张,间质炎症浸润和胶原沉积增加，伴脂质沉积；电镜提示线粒体密度减少、肿胀，嵴断裂减少甚至消失。PPAR-α、CPT1-α mRNA及Bcl-2蛋白表达降低；Bax、Caspase-3、C-Caspase-3、Bax/Bcl-2、C-Caspase-3/Caspase-3蛋白表达上调（均P<0.05）。与模型组比较，FSXZF高剂量组大鼠肌酐、尿素氮、24 h-UTP明显下降（均P<0.05）；FSXZF各剂量组肾脏指数降低（均P<0.05），肾脏病理明显改善，脂质沉积减少，线粒体肿胀和嵴损伤缓解；同时上调PPAR-α、CPT1-α mRNA及Bcl-2蛋白表达，下调Bax、C-Caspase-3及相关比值（均P<0.05）。结论：FSXZF可有效缓解腺嘌呤诱导的CKD大鼠肾功能损伤，改善肾脏组织病理及抑制肾纤维化进展，其保护机制可能与调节肾脏脂肪酸代谢，进而抑制肾纤维化有关。
Abstract:
Objective:To investigate Fushen Xiezhuo formula (FSXZF) attenuates adenine-induced renal fibrosis in chronic kidney disease (CKD) rats by modulating renal fatty acid metabolism.Methods:Thirty-two SPF male sprague-dawley rats were randomly assigned to four groups (n=8):control group,model group, low-dose FSXZF (FSXZF-L) group and high-dose FSXZF (FSXZF-H) group.Except for the control group,rats received adenine for 3 consecutive weeks to establish a CKD model,followed by FSXZF administration at 16.3 or 32.5 g/（kg·d） for 4 weeks in the FSXZF-L and FSXZF-H groups,respectively.Body weight and kidney index were recorded.Serum creatinine (SCr),blood urea nitrogen (BUN),uric acid (UA) and 24-h urinary protein were measured.Renal histopathology and collagen volume fraction were evaluated by hematoxylin-eosin (HE) and Masson staining.Lipid deposition was assessed by oil red O staining.And mitochondrial ultrastructure was observed by transmission electron microscopy.Protein expression of Bcl-2-associated X protein (Bax),B-cell lymphoma-2 (Bcl-2),Caspase-3 and Cleaved Caspase-3 in renal tissue was detected by Western blotting.mRNA expression of carnitine palmitoyltransferase-1α (CPT1-α) and peroxisome proliferator-activated receptor α (PPAR-α) was determined by real-time PCR.Results:Compared with the blank group,the body weight of rats in the model group decreased,the kidney weight and kidney index increased,and the renal function indicators significantly declined (all P<0.05).Pathology showed glomerular atrophy,basement membrane thickening,tubular dilation,increased interstitial inflammatory infiltration and collagen deposition,accompanied by lipid deposition in rats.Electron microscopy showed a decrease in mitochondrial density,swelling,and a decrease or even disappearance of broken cristae.The expression of PPAR-α,CPT1-α mRNA and Bcl-2 protein decreased.The expression of Bax,Caspase-3,C-Caspase-3,Bax/Bcl-2,C-Caspase-3/Caspase-3 proteins was up-regulated (all P<0.05).Compared with the model group,the levels of creatinine,blood urea nitrogen and 24 h-UTP in rats of the high-dose FSXZF group decreased significantly (all P<0.05).The kidney index decreased in all FSXZF dose groups (all P<0.05),the renal pathology improved significantly,lipid deposition decreased,and mitochondrial swelling and cristae damage were alleviated.At the same time,the expression of PPAR-α,CPT1-α mRNA and Bcl-2 protein was up-regulated,and the expression of Bax,C-Caspase-3 and related ratios was down-regulated (all P<0.05).Conclusion:FSXZF effectively ameliorates adenine-induced renal dysfunction,improves renal histopathological injury and inhibits the progression of renal fibrosis in CKD rats.Its nephroprotective effects may be associated with modulation of renal fatty acid metabolism,thereby suppressing renal fibrosis.

参考文献/References:

[1]ROMAGNANI P，AGARWAL R，CHAN J C N，et al.Chronic kidney disease[J].Nat Rev Dis Primers，2025，11（1）：8.
[2]KIDNEY DISEASE:IMPROVING GLOBAL OUTCOMES (KDIGO) CKD WORK GROUP.KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease[J].Kidney Int，2024，105（4S）：S117-S314.
[3]MITROFANOVA A，MERSCHER S，FORNONI A.Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease[J].Nat Rev Nephrol，2023，19（10）：629-645.
[4]GUPTA P，ZHU S，GUI Y，et al.Metabolic chaos in kidney disease:Unraveling energy dysregulation[J].J Clin Med，2024，13（22）：6772.
[5]WEI X，HOU Y，LONG M，et al.Advances in energy metabolism in renal fibrosis[J].Life Sci，2023，312：121033.
[6]CHEN X，MAO Y，HU J，et al.Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes[J].Diabetes，2021，70（10）：2322-2332.
[7]陆蕾，姜鸿，舒占钧，等.复肾泄浊汤治疗慢性肾脏病脾肾两虚证的疗效观察[J].新疆医科大学学报（医学版），2024，47（11）：1528-1532，1538.
[8]刘晓，李悦，舒占钧，等.不同剂量腺嘌呤建立脾肾阳虚型慢性肾衰竭大鼠模型的实验研究[J].新疆医科大学学报（医学版），2024，47（2）：197-202.
[9]吕昌洋，范汝鹏，赵茜曼，等.白术多糖对Cr（Ⅵ）诱导PK-15细胞凋亡和小鼠肾损伤的影响[J].动物医学进展，2024，45（3）：59-66.
[10]张冉冉.人参皂苷Rb1通过线粒体自噬缓解3-氯-1,2-丙二醇诱导的肾细胞焦亡[D].长春：吉林大学，2023.
[11]王玲.黄芪提取物改善高脂血症的机制探究[D].长沙：中南大学，2022.
[12]胡汝明，谢岳婷，陈剑川.基于AKT/GSK-3β信号通路探讨熟地黄提取物对糖尿病肾病大鼠肾小球脏层上皮细胞表型转化的影响[J].中国老年学杂志，2023，43（10）：2497-2500.
[13]莫逊，余姗姗，贾静，等.茯苓酸通过抑制炎症和肾小管上皮细胞凋亡减轻脂多糖诱导的急性肾损伤[J].中国病理生理杂志，2025，41（5）：995-1005.
[14]马良，张薇，王雨典，等.中药调控TGF-β通路介导的自噬防治肾纤维化[J].中医学报，2025，40（6）：1139-1145.
[15]闫晓欢，孙乔，吴振华，等.大黄及其中药复方干预肾脏纤维化研究进展[J].陕西中医，2025，46（9）：1294-1297.
[16]马海兰，马鸿斌，李旭萍，等.水蛭地龙有效组分及其配伍防治肾纤维化的研究进展[J].中医药临床杂志，2025，37（1）：187-193.
[17]陶钰，周柯，黄诗棋，等.三七对肾纤维化大鼠肾脏细胞线粒体途径凋亡的影响[J].时珍国医国药，2024，35（6）：1341-1344.
[18]胡超娜，高继宁.益肾泄浊方对肾纤维化大鼠的治疗作用及机制[J].山西医科大学学报（医学版），2024，55（1）：57-64.
[19]刘静，江蕾，曹红娣.线粒体脂肪酸β氧化缺陷在慢性肾脏病肾小管损伤发病和治疗中的研究进展[J].山东医药，2024，64（4）：92-95.
[20]吴斯琦，丁萌譞，舒占钧.参芪地黄汤加味对脂多糖诱导人肾小管上皮细胞TLRs/NF-κB信号通路的影响[J].陕西中医，2025，46（3）：320-324.
[21]XU W，ZHU Y，WANG S，et al.From adipose to ailing kidneys:The role of lipid metabolism in obesity-related chronic kidney disease[J].Antioxidants（Basel），2024，13（12）：1540.
[22]陈寅清，韩世盛，王怡.肾小管上皮细胞脂肪酸代谢与脂质肾毒性的研究进展[J].重庆医学，2024，53（17）：2677-2681.
[23]LI J，YANG Y，LI Q，et al.STAT6 contributes to renal fibrosis by modulating PPARα-mediated tubular fatty acid oxidation[J].Cell Death Dis，2022，13（1）：66.
[24]孟玲飞，刘欣欣，朱映黎，等.基于PKA/PPARα/CPT1α通路探讨附子调控阳虚小鼠肝脏脂质代谢的作用机制[J].中国实验方剂学杂志，2025，31（14）：40-48.
[25]CHEN Y，LIU F，DAI R，et al.Mechanisms and therapeutic potential of multiple forms of programmed cell death in renal fibrosis[J].Cell Signal，2025，134：111926.
[26]YANG Y，YANG W，HU T，et al.Protective effect of biochanin A on gamma radiation-induced oxidative stress, antioxidant status, apoptotic, and DNA repairing molecules in Swiss albino mice[J].Cell Biochem Funct，2024，42（8）：e70005.
[27]赵悦如，马善波，赵晋.急性肾损伤过程中肾小管上皮细胞的衰老机制与命运转归[J].陕西医学杂志，2025，54（10）：1432-1435，1441.

相似文献/References:

[1]屈 凯,王悦彤,王漱非,等.基于文献研究探讨益肾散结法防治肾小球硬化的理论内涵*[J].陕西中医,2019,(7):919.
　QU Kai,WANG Yuetong,WANG Shufei,et al.Based on literature research to explore the theoretical connotation of Kidney-reinforcing and Mass-disintegrating for prevention and treatment of glomerulosclerosis[J].,2019,(4):919.
[2]任永朋,华 琼,刘彦妍,等.中医“治未病”思想在防治肾脏病中的应用*[J].陕西中医,2019,(8):1101.
　REN Yongpeng,HUA Qiong,LIU Yanyan,et al.The application of the thought of “preventive treatment of disease” in the prevention and treatment of kidney disease in traditional Chinese medicine[J].,2019,(4):1101.
[3]张宏强,李桂霞,章彩凤,等.许筠治疗慢性肾病临床药对举隅*[J].陕西中医,2020,(6):808.[doi:DOI:10.3969/j.issn.10007369.2020.06.031]
[4]陈紫薇,陈 明△.从脾论治慢性肾脏病的生物学基础探讨*[J].陕西中医,2020,(11):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
　CHEN Ziwei,CHEN Ming..Discuss the biological foundation for chronic disease therapy from treatment through the spleen[J].,2020,(4):1627.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.029]
[5]董 怡,马 静,余楠楠,等.大黄复方保留灌肠辅助治疗慢性肾脏病疗效及对患者生活质量的影响[J].陕西中医,2021,(7):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
　DONG Yi,MA Jing,YU Nannan,et al.Effect analysis of rhubarb compound retention enema adjuvant treatment of chronic kidney disease and its impact on patients' quality of life[J].,2021,(4):910.[doi:DOI:10.3969/j.issn.1000-7369.2020.07.026]
[6]齐 宁,宋姝西,刘香玉,等.参芪延肾方治疗慢性肾脏病疗效及对患者半乳糖缺陷IgA1、晚期糖基化终产物和微炎性反应状态的影响[J].陕西中医,2022,(5):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
　QI Ning,SONG Shuxi,LIU Xiangyu,et al.Effects of Shenqi Yanshen recipe on the levels of Gd-IgA1,AGEs and micro inflammatory response in patients with chronic kidney disease[J].,2022,(4):596.[doi:DOI:10.3969/j.issn.1000-7369.2022.05.012]
[7]麦芳雄,张香兰,朱德礼.温肾健脾清化汤辅助治疗脾肾气虚型慢性肾脏病疗效及对患者血清转化生长因子β1、纤维连接蛋白水平的影响[J].陕西中医,2022,(8):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
　MAI Fangxiong,ZHANG Xianglan,ZHU Deli.Clinical efficacy of Wenshen Jianpi Qinghua decoction in the treatment of chronic kidney disease with spleen-kidney qi deficiency and its effect on serum transforming growth factor β1 and fibronectin levels[J].,2022,(4):1068.[doi:DOI:10.3969/j.issn.1000-7369.2022.08.019]
[8]杨淑彬,李 婷,李晓妮,等.不同中药结肠透析模式对慢性肾脏病患者胃肠道症状和营养状态的影响[J].陕西中医,2022,(12):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
　YANG Shubin,LI Ting,LI Xiaoni,et al.Effects of different colon dialysis modes of traditional Chinese medicine on gastrointestinal symptoms and nutritional status in patients with chronic kidney disease[J].,2022,(4):1698.[doi:DOI:10.3969/j.issn.1000-7369.2022.12.010]
[9]陈 曦,董凯旋,周 荣,等.中药调控p38丝裂原活化蛋白激酶/核因子κB通路治疗肾纤维化研究进展[J].陕西中医,2023,(7):980.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
　CHEN Xi,DONG Kaixuan,ZHOU Rong,et al.Research progress of traditional Chinese medicine regulating p38MAPK/NF-κB pathway in treatment of renal fibrosis[J].,2023,(4):980.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.036]
[10]周 林,禹 红,刘毓玲,等.活肾通络方联合依那普利对慢性肾脏病患者纤维化标志物、人附睾蛋白4水平的影响[J].陕西中医,2023,(10):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]
　ZHOU Lin,YU Hong,LIU Yuling,et al.Effect of Huoshen Tongluo decoction and enalapril on renal function,fibrosis markers and HE4 levels in patients with chronic renal disease[J].,2023,(4):1400.[doi:DOI:10.3969/j.issn.1000-7369.2023.10.014]
[11]岳靓,米秀华,杨柳易.补虚祛风方对5/6(A/I)大鼠肾纤维化的影响及机制研究[J].陕西中医,2025,46(9):1160.[doi:DOI:10.3969/j.issn.1000-7369.2025.09.002]
　YUE Liang,MI Xiuhua,YANG Liuyi.Effect and mechanism of Buxu Qufeng prescription on renal interstitial fibrosis in 5/6(A/I) rats[J].,2025,46(4):1160.[doi:DOI:10.3969/j.issn.1000-7369.2025.09.002]
[12]汪六林,李刚,刘祺,等.大黄素调节消皮素蛋白E通路的细胞焦亡改善UUO小鼠肾脏纤维化的机制研究[J].陕西中医,2026,(3):291.[doi:DOI:10.3969/j.issn.1000-7369.2026.03.001]
　WANG Liulin,LI Gang,LIU Qi,et al.Study on the mechanism of emodin regulating GSDME pathway-induced pyroptosis to improve renal fibrosis in UUO mice[J].,2026,(4):291.[doi:DOI:10.3969/j.issn.1000-7369.2026.03.001]

备注/Memo

备注/Memo:
新疆维吾尔自治区“天山英才”医药卫生高层次人才项目（TSYC202401A063）；新疆维吾尔自治区中医医院中医药传承创新中心临床研究孵化基金资助项目（2025CC02）；新疆维吾尔自治区中医医院科研项目（YYZJ2024-002）
更新日期/Last Update: 2026-04-05